AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML): Phase 1b results
| मुख्य लेखकों: | , , , , , , , , , , , , , , , , , , |
|---|---|
| स्वरूप: | Conference item |
| भाषा: | English |
| प्रकाशित: |
Elsevier
2022
|
| _version_ | 1826310918575751168 |
|---|---|
| author | Daver, N Vyas, P Kambhampati, S Malki, MA Larson, R Asch, A Mannis, G Chai-Ho, W Tanaka, T Bradley, T Jeyakumar, D Wang, E Xing, G Chao, M Ramsingh, G Renard, C Lal, I Zeidner, J Sallman, D |
| author_facet | Daver, N Vyas, P Kambhampati, S Malki, MA Larson, R Asch, A Mannis, G Chai-Ho, W Tanaka, T Bradley, T Jeyakumar, D Wang, E Xing, G Chao, M Ramsingh, G Renard, C Lal, I Zeidner, J Sallman, D |
| author_sort | Daver, N |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-07T08:00:37Z |
| format | Conference item |
| id | oxford-uuid:83e9ca0f-e05b-457a-a97e-32a8f27bd9b9 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T08:00:37Z |
| publishDate | 2022 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:83e9ca0f-e05b-457a-a97e-32a8f27bd9b92023-09-25T12:27:47ZAML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML): Phase 1b resultsConference itemhttp://purl.org/coar/resource_type/c_c94fuuid:83e9ca0f-e05b-457a-a97e-32a8f27bd9b9EnglishSymplectic ElementsElsevier2022Daver, NVyas, PKambhampati, SMalki, MALarson, RAsch, AMannis, GChai-Ho, WTanaka, TBradley, TJeyakumar, DWang, EXing, GChao, MRamsingh, GRenard, CLal, IZeidner, JSallman, D |
| spellingShingle | Daver, N Vyas, P Kambhampati, S Malki, MA Larson, R Asch, A Mannis, G Chai-Ho, W Tanaka, T Bradley, T Jeyakumar, D Wang, E Xing, G Chao, M Ramsingh, G Renard, C Lal, I Zeidner, J Sallman, D AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML): Phase 1b results |
| title | AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML): Phase 1b results |
| title_full | AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML): Phase 1b results |
| title_fullStr | AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML): Phase 1b results |
| title_full_unstemmed | AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML): Phase 1b results |
| title_short | AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML): Phase 1b results |
| title_sort | aml 464 tolerability and efficacy of the first in class anti cd47 antibody magrolimab combined with azacitidine in frontline patients with tp53 mutated acute myeloid leukemia aml phase 1b results |
| work_keys_str_mv | AT davern aml464tolerabilityandefficacyofthefirstinclassanticd47antibodymagrolimabcombinedwithazacitidineinfrontlinepatientswithtp53mutatedacutemyeloidleukemiaamlphase1bresults AT vyasp aml464tolerabilityandefficacyofthefirstinclassanticd47antibodymagrolimabcombinedwithazacitidineinfrontlinepatientswithtp53mutatedacutemyeloidleukemiaamlphase1bresults AT kambhampatis aml464tolerabilityandefficacyofthefirstinclassanticd47antibodymagrolimabcombinedwithazacitidineinfrontlinepatientswithtp53mutatedacutemyeloidleukemiaamlphase1bresults AT malkima aml464tolerabilityandefficacyofthefirstinclassanticd47antibodymagrolimabcombinedwithazacitidineinfrontlinepatientswithtp53mutatedacutemyeloidleukemiaamlphase1bresults AT larsonr aml464tolerabilityandefficacyofthefirstinclassanticd47antibodymagrolimabcombinedwithazacitidineinfrontlinepatientswithtp53mutatedacutemyeloidleukemiaamlphase1bresults AT ascha aml464tolerabilityandefficacyofthefirstinclassanticd47antibodymagrolimabcombinedwithazacitidineinfrontlinepatientswithtp53mutatedacutemyeloidleukemiaamlphase1bresults AT mannisg aml464tolerabilityandefficacyofthefirstinclassanticd47antibodymagrolimabcombinedwithazacitidineinfrontlinepatientswithtp53mutatedacutemyeloidleukemiaamlphase1bresults AT chaihow aml464tolerabilityandefficacyofthefirstinclassanticd47antibodymagrolimabcombinedwithazacitidineinfrontlinepatientswithtp53mutatedacutemyeloidleukemiaamlphase1bresults AT tanakat aml464tolerabilityandefficacyofthefirstinclassanticd47antibodymagrolimabcombinedwithazacitidineinfrontlinepatientswithtp53mutatedacutemyeloidleukemiaamlphase1bresults AT bradleyt aml464tolerabilityandefficacyofthefirstinclassanticd47antibodymagrolimabcombinedwithazacitidineinfrontlinepatientswithtp53mutatedacutemyeloidleukemiaamlphase1bresults AT jeyakumard aml464tolerabilityandefficacyofthefirstinclassanticd47antibodymagrolimabcombinedwithazacitidineinfrontlinepatientswithtp53mutatedacutemyeloidleukemiaamlphase1bresults AT wange aml464tolerabilityandefficacyofthefirstinclassanticd47antibodymagrolimabcombinedwithazacitidineinfrontlinepatientswithtp53mutatedacutemyeloidleukemiaamlphase1bresults AT xingg aml464tolerabilityandefficacyofthefirstinclassanticd47antibodymagrolimabcombinedwithazacitidineinfrontlinepatientswithtp53mutatedacutemyeloidleukemiaamlphase1bresults AT chaom aml464tolerabilityandefficacyofthefirstinclassanticd47antibodymagrolimabcombinedwithazacitidineinfrontlinepatientswithtp53mutatedacutemyeloidleukemiaamlphase1bresults AT ramsinghg aml464tolerabilityandefficacyofthefirstinclassanticd47antibodymagrolimabcombinedwithazacitidineinfrontlinepatientswithtp53mutatedacutemyeloidleukemiaamlphase1bresults AT renardc aml464tolerabilityandefficacyofthefirstinclassanticd47antibodymagrolimabcombinedwithazacitidineinfrontlinepatientswithtp53mutatedacutemyeloidleukemiaamlphase1bresults AT lali aml464tolerabilityandefficacyofthefirstinclassanticd47antibodymagrolimabcombinedwithazacitidineinfrontlinepatientswithtp53mutatedacutemyeloidleukemiaamlphase1bresults AT zeidnerj aml464tolerabilityandefficacyofthefirstinclassanticd47antibodymagrolimabcombinedwithazacitidineinfrontlinepatientswithtp53mutatedacutemyeloidleukemiaamlphase1bresults AT sallmand aml464tolerabilityandefficacyofthefirstinclassanticd47antibodymagrolimabcombinedwithazacitidineinfrontlinepatientswithtp53mutatedacutemyeloidleukemiaamlphase1bresults |